Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

European Urology

Volumn 71, Issue 2, 2017, Pages 151-154

  Beer, Tomasz M ^a   Armstrong, Andrew J ^b   Rathkopf, Dana ^c   Loriot, Yohann ^d   Sternberg, Cora N ^e   Higano, Celestia S ^f   Iversen, Peter ^g   Evans, Christopher P ^h   Kim, Choung Soo ⁱ   Kimura, Go ^j   Miller, Kurt ^k   Saad, Fred ^l   Bjartell, Anders S ^m   Borre, Michael ⁿ   Mulders, Peter ^o   Tammela, Teuvo L ^p   Parli, Teresa ^q   Sari, Suha ^q   van Os, Steve ^r   Theeuwes, Ad ^r   Tombal, Bertrand ^s   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f UNIVERSITY OF WASHINGTON   (United States)

^g University of Copenhagen   (Denmark)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Asan Medical Center   (South Korea)

^j NIPPON MEDICAL SCHOOL   (Japan)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^m LUND UNIVERSITY HOSPITAL   (Sweden)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^p TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^q Medivation Inc   (United States)

^r Astellas Pharma Global Development   (Netherlands)

^s CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

Androgen receptor signaling inhibitor; Enzalutamide; Metastatic castration resistant prostate cancer; Overall survival; Radiographic progression free survival

Indexed keywords

ENZALUTAMIDE; PLACEBO; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ARTHRALGIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOLLOW UP; HUMAN; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS;

EID: 84979787889     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.07.032     Document Type: Article

References (6)

1. [1] Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
2. [2] Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
3. [3] de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
4. [4] Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
5. [5] Higano, C.S., Beer, T.M., Taplin, M.E., et al. Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol 68 (2015), 795–801.
6. [6] Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26 (2008), 1148–1159.